Most of your cost is avoidable. We help you steer care sooner—toward better outcomes and lower spend.
Protect your workforce. Reduce high-cost episodes. Stay compliant.
Lower total cancer spend with earlier, smarter interventions.
Offer better cancer care options—without raising premiums or legal risk.
Cancer care is your fastest-growing cost—and you’re stuck with the bill.
By the time most employees access advanced options, it’s too late, too expensive, and too fragmented to help.
You can’t keep absorbing that hit. But you also can’t deny care.
There’s a smarter path—if you can see it.
of Americans are on self-funded plans
Cancer care is now the #1 driver of total healthcare spend
Under CAA-21, employers and payers now carry legal risk for doing nothing
Without full testing, missed precision medicine opportunities
Full testing at diagnosis (yet 60% of cancer drugs recommend biomarker testing)
Missed clinical trial opportunities
(where pharma sponsors the drug)
Patients in trials
(yet up to 50% eligible)
Setting makes a difference in cost
and jumping systems leads to
inefficiency & duplication
Higher chemotherapy cost in
hospital setting
1104Health™: Comprehensive, Low-Lift Cancer Solution That
Controls Spend and Activates Oncologists to Deliver Better Care
Solving the WHOLE and engaging the decision makers, community oncologists
Clinical trials aren’t last resorts. They’re often the best care option—but they’re completely invisible to most employees.
We help you identify trial-eligible members, connect them to high value local oncologists, and offload their treatment costs—before you spend six figures on salvage care.
You lower spend. They get options. Everyone wins early.
We make it simple to take action—without adding more complexity to your team.
● No implementation or PEPM cost
● Flat fee per tested member
● Value realized if 1 in 10 tested
membersʼ care is redirected
● Incorporates clinical trials as a treatment option
● Engaging the decision makers –
community oncologists
● Not reliant on patient activation
